A second barrier to an effective antitumor immunity relates to the lack of expression of costimulatory molecules in cancer cells.17 To overcome this intrinsic tumor challenge, we armed Delta-24-RGD to express GITRL on the surface of infected cancer cells, where it will be able to engage with GITR molecules present on the immune cells. This evidence concerns the gene TNFRSF18 and cancer.